Jia Jie Biomedical Co., Ltd. (TPEX:4109)
Taiwan · Delayed Price · Currency is TWD 11.35
-0.05 (-0.44%)
Aug 19, 2026, 11:10 AM CST
Jia Jie Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 514.65 | 485.4 | 537.07 | 332.76 | 317.72 | 242.48 | |
Revenue Growth | 10.74% | -9.62% | 61.40% | 4.73% | 31.03% | -10.29% |
Cost of Revenue | 375.96 | 335.07 | 363.72 | 215.12 | 201.21 | 158.71 |
Gross Profit | 138.7 | 150.34 | 173.35 | 117.64 | 116.51 | 83.77 |
Selling, General & Admin | 143.15 | 142.9 | 133.58 | 174.79 | 121.96 | 81.39 |
Research & Development | 7.05 | 6.74 | 6.55 | 9.32 | 8.94 | 3.61 |
Operating Expenses | 150.2 | 149.63 | 140.18 | 183.84 | 130.19 | 84.7 |
Operating Income | -11.51 | 0.71 | 33.17 | -66.2 | -13.68 | -0.93 |
Interest Expense | -1.06 | -0.28 | -0.64 | -0.35 | -0.11 | -0.06 |
Interest & Investment Income | 11.28 | 11.01 | 3.49 | 6.76 | 3.83 | 0.59 |
Earnings From Equity Investments | - | - | - | 0.31 | - | - |
Currency Exchange Gain (Loss) | - | - | 0.47 | 0.29 | -0.29 | -0.49 |
Other Non Operating Income (Expenses) | -36.23 | 8.17 | 5.83 | 5.61 | 5.07 | 4.19 |
EBT Excluding Unusual Items | -37.52 | 19.61 | 42.32 | -53.59 | -5.19 | 3.3 |
Gain (Loss) on Sale of Investments | 40.24 | 40.24 | 183.75 | 200.25 | - | - |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | -0.58 | -0.12 | 0.48 | -0.53 |
Other Unusual Items | - | - | - | 0.01 | 0.04 | 2.52 |
Pretax Income | 2.73 | 59.86 | 225.49 | 146.55 | -4.68 | 5.29 |
Income Tax Expense | -0.92 | 7.75 | 9.34 | -0.48 | 1.76 | 0.19 |
Earnings From Continuing Operations | 3.65 | 52.12 | 216.15 | 147.02 | -6.44 | 5.1 |
Minority Interest in Earnings | -0.56 | -1.86 | -4.78 | -2.88 | 0.97 | 0.24 |
Net Income | 3.09 | 50.26 | 211.37 | 144.15 | -5.47 | 5.34 |
Net Income to Common | 3.09 | 50.26 | 211.37 | 144.15 | -5.47 | 5.34 |
Net Income Growth | - | -76.22% | 46.64% | - | - | - |
Shares Outstanding (Basic) | 118 | 116 | 98 | 89 | 89 | 89 |
Shares Outstanding (Diluted) | 118 | 117 | 98 | 89 | 89 | 89 |
Shares Change | 10.74% | 18.72% | 10.08% | 0.29% | - | 28.10% |
EPS (Basic) | 0.03 | 0.43 | 2.16 | 1.62 | -0.06 | 0.06 |
EPS (Diluted) | 0.03 | 0.43 | 2.15 | 1.62 | -0.06 | 0.06 |
EPS Growth | - | -80.00% | 32.72% | - | - | - |
Free Cash Flow | -52.35 | -64.15 | 24.72 | -13.1 | -26.64 | 2.85 |
Free Cash Flow Per Share | -0.44 | -0.55 | 0.25 | -0.15 | -0.30 | 0.03 |
Dividend Per Share | - | 0.200 | 0.500 | 0.500 | - | - |
Dividend Growth | - | -60.00% | 0% | - | - | - |
Gross Margin | 26.95% | 30.97% | 32.28% | 35.35% | 36.67% | 34.55% |
Operating Margin | -2.24% | 0.15% | 6.18% | -19.89% | -4.31% | -0.38% |
Profit Margin | 0.60% | 10.35% | 39.36% | 43.32% | -1.72% | 2.20% |
Free Cash Flow Margin | -10.17% | -13.22% | 4.60% | -3.94% | -8.38% | 1.18% |
EBITDA | 5.93 | 15.6 | 46.24 | -54.19 | -0.58 | 10.05 |
EBITDA Margin | 1.15% | 3.21% | 8.61% | -16.29% | -0.18% | 4.14% |
D&A For EBITDA | 17.44 | 14.89 | 13.07 | 12.01 | 13.11 | 10.98 |
EBIT | -11.51 | 0.71 | 33.17 | -66.2 | -13.68 | -0.93 |
EBIT Margin | -2.24% | 0.15% | 6.18% | -19.89% | -4.31% | -0.38% |
Effective Tax Rate | - | 12.94% | 4.14% | - | - | 3.61% |